A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Completed	`NCT00729586` - Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	Phase 2
Completed	`NCT00756847` - Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors	Phase 1
Completed	`NCT02983279` - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer	N/A
Completed	`NCT02017353` - Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma	Phase 2
Completed	`NCT00997373` - Letrozole as a Treatment of Endometrial Cancer	N/A
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Recruiting	`NCT04576104` - Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer	Phase 2
Not yet recruiting	`NCT06102252` - Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma	N/A
Active, not recruiting	`NCT02598219` - Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.	Phase 3
Recruiting	`NCT04159155` - A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer	Phase 2/Phase 3
Recruiting	`NCT05139368` - Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer	N/A
Recruiting	`NCT02611024` - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors	Phase 1/Phase 2
Completed	`NCT03849469` - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors	Phase 1
Suspended	`NCT06253494` - Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03917381` - GEN1046 Safety Trial in Patients With Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT03372720` - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors	N/A
Recruiting	`NCT06413992` - Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer	Phase 2
Recruiting	`NCT05316467` - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma	Phase 2/Phase 3

NCT number	NCT05121363
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Beihua Kong, Doctor
Phone	18560081888
Email	kongbeihua@sdu.edu.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	December 2021
Completion date	July 2023

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms